Table of Contents

2019 Month : July Volume : 8 Issue : 26 Page : 2043-2046

URINARY N TELOPEPTIDE- THE IDEAL BIOMARKER FOR OSTEOPOROSIS.

Ganesan G. Ram1, N. Jambu2

1Associate Professor, Department of Orthopaedics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamilnadu India.
2Professor, Department of Orthopaedics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamilnadu India.

References :

1

Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis International 2006;17(12):1726-33.              

CrossRef | Google Scholar | PubMed
2

Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet 1999;353(9156):878-82.                              

CrossRef | Google Scholar | PubMed
3

Pisani P, Renna MD, Conversano F, et al. Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World Journal of Radiology 2013;5(11):398-410.                     

CrossRef | Google Scholar | PubMed
4

Carlson-Newberry SJ, Costello RB. Emerging technologies for nutrition research: potential for assessing military performance capability. Institute of Medicine (US) Committee on Military Nutrition Research. Washington (DC): National Academies Press (US) 1997. ISBN-10: 0-309-05797-3.

5

Shetty S, Kapoor N, Bondu JD, et al. Bone turnover markers: emerging tool in the management of osteoporosis. Indian Journal of Endocrinology and Metabolism 2016;20(6):846-52.        

CrossRef | Google Scholar | PubMed
6

Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine. Journal of Bone and Mineral Research 1992;7(11):1251-8.             

Google Scholar | PubMed
7

Bonde M, Qvist P, Fledelius C, et al. Immunoassay for quantifying type 1 collagen degradation products in urine evaluated. Clinical Chemistry 1994;40(11 Pt 1):2022-5.    

CrossRef | Google Scholar | PubMed
8

Rabar S, Lau R, O’Flynn N, et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012;345:e3698.           

CrossRef | Google Scholar | PubMed
9

Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporosis International 2001;12(5):417-27.           

CrossRef | Google Scholar | PubMed
10

Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. The Lancet 2002;359(9321):1929-36.                          

CrossRef | Google Scholar | PubMed
11

Gubala V, Harris LF, Ricco AJ, et al. Point of care diagnostics: status and future. Analytical Chemistry 2012;84(2):487-515.    

CrossRef | Google Scholar | PubMed
12

Liu L, Webster TJ. In situ sensor advancements for osteoporosis prevention, diagnosis and treatment. Current Osteoporosis Reports 2016;14(6):386-95.          

CrossRef | Google Scholar | PubMed
13

Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Research 2017;5(1):18.                                   

CrossRef | Google Scholar | PubMed
14

Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis International 2000;11(Suppl 6):S2-S17.     

Google Scholar | PubMed
15

Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocrine Practice 1996;2(1):13-9.              

CrossRef | Google Scholar | PubMed
16

Lombardi G, Lanteri P, Colombini A, et al. Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clinical Chemistry and Laboratory Medicine 2012;50(5):771-89.          

CrossRef | Google Scholar | PubMed
17

Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clinical Chemistry 2017;63(2):464-74.   

CrossRef | Google Scholar | PubMed
18

Fatayerji D, Eastell R. Age‐related changes in bone turnover in men. Journal of Bone and Mineral Research 1999;14(7):1203-10.    

CrossRef | Google Scholar | PubMed
19

Khosla S, Atkinson EJ, Melton LJ 3rd, et al. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. The Journal of Clinical Endocrinology & Metabolism 1997;82(5):1522-7.               

CrossRef | Google Scholar | PubMed
20

Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. The Journal of Clinical Endocrinology & Metabolism 1996;81(9):3366-71.                   

CrossRef | Google Scholar | PubMed
21

Bell NH, Hollis BW, Shary JR, et al. Diclofenac sodium inhibits bone resorption in postmenopausal women. The American Journal of Medicine 1994;96(4):349-53.            

CrossRef | Google Scholar | PubMed
22

Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309(6956):691-5.              

CrossRef | Google Scholar | PubMed
23

Wishart JM, Need AG, Horowitz M, et al. Effect of age on bone density and bone turnover in men. Clinical Endocrinology 1995;42(2):141-6.               

CrossRef | Google Scholar | PubMed